Clinical Trials Network: Pacific Northwest Node

$791,361UG1FY2025DANIH

University Of Washington, Seattle WA

Investigators

Linked publications, trials & patents

Paper 39733196 Paper 39570250 Paper 39550823 Paper 39175066 Paper 38875880 Paper 38648174 Paper 38513976 Paper 38447393 Paper 38315721 Paper 38097045 Paper 37930512 Paper 37902748 Paper 37863356 Paper 37792357 Paper 37583120 Paper 37537988 Paper 37163263 Paper 37132085 Paper 37074350 Paper 36857542 Paper 36801204 Paper 36202737 Paper 35773113 Paper 35752520 Paper 35707859 Paper 35651523 Paper 35605529 Paper 35452194 Paper 35409790 Paper 35293064 Paper 35111898 Paper 35109940 Paper 35076700 Paper 34884523 Paper 34870109 Paper 34698397 Paper 34555691 Paper 34264739 Paper 34264326 Paper 34233750 Paper 34170188 Paper 34105213 Paper 34075644 Paper 33950535 Paper 33879260 Paper 33569735 Paper 33517894 Paper 33509278 Paper 33342667 Paper 33307301 Paper 33097315 Paper 32873500 Paper 32741496 Paper 32438502 Paper 32353544 Paper 32220411 Paper 32220410 Paper 32220408 Paper 32220405 Paper 32220404 Paper 32142055 Paper 31952624 Paper 31835068 Paper 31712969 Paper 31704382 Paper 31689297 Paper 31365138 Paper 30557443 Paper 30452209 Paper 30106494 Paper 30094695 Paper 29914717 Paper 29672167 Paper 29561290 Paper 29528783 Paper 29433535 Paper 29195590 Paper 29150198 Paper 29112827 Paper 29035917 Paper 28623823 Paper 28513227 Paper 28426361 Paper 28368740 Paper 28317510 Paper 28068121 Paper 27958381 Paper 27898496 Paper 27766067 Paper 27624618 Paper 27442691 Paper 27294812 Paper 26948856 Paper 26880594 Paper 26820608 Paper 26743586 Paper 26599131 Paper 26456717 Paper 26389639 Paper 25908321

Abstract

Evolving trends around opioids, methamphetamine, legalized cannabis, and stigma have led to prioritization of several themes in addiction treatment research. Innovations in MOUD treatment, overdose prevention, harm reduction strategies, and novel therapeutics and technologies are needed to address the leading challenges in SUD treatment. To carry out to the objectives and research priorities of the NIDA Drug Abuse Treatment Clinical Trials Network (CTN), the Pacific Northwest (PNW) Node proposes the following Specific Aims: 1) Increase capacity of the PNW Node research team by expanding investigators who bring practical and clinical expertise and an encompassing lens to their work in opioid, methamphetamine, and other drugs of abuse; substance use impacts on youth and families; emerging behavioral, neuromodulation and pharmacologic treatments; SUD treatment access in primary care (PC); and harm reduction strategies. 2) Expand scope, population, and focus of PNW Nodeâs roster of research, practice, and dissemination settings. We will do this by including new settings for SUD treatment and PC, and partnerships with individuals and organizations focusing on drug and alcohol related policy in the Pacific Northwest. 3) Design and conduct pragmatic, comparative effectiveness, implementation, data science, and other types of studies that evaluate novel behavioral, pharmacological, and technology-based treatments for opioids, methamphetamine, and cannabis. Studies will be informed bi-directionally by SUD researchers, clinicians, primary and acute care providers and our community advisory board, and enhanced where appropriate by use of Electronic Health Records to ensure representation of all groups. 4) Provide dissemination, workforce training, and technical assistance to affiliated SUD and healthcare providers, researchers, and the public about SUDs, medication treatments, and behavioral interventions integrated into settings serving people who use substances. We will use strategic cross-node collaborations and UW/WSU training, technical assistance and dissemination programs to complete this work.

View original record on NIH RePORTER →